

I_135_0502-6

135th General Assembly
Regular Session
2023-2024

Sub. H. B. No. 73

A BILL

To enact section 3792.06 of the Revised Code to
authorize the prescribing of off-label
medications and if prescribed, to generally
require their dispensing and to name this act
the Dave and Angie Patient and Health Provider
Protection Act.

BE IT ENACTED BY THE GENERAL ASSEMBLY OF THE STATE OF OHIO:

Section 1. That section 3792.06 of the Revised Code be
enacted to read as follows:

Sec. 3792.06. (A) As used in this section:

(1) "Health-related licensing board" has the same meaning
as in section 3719.062 of the Revised Code.

(2) "Hospital" has the same meaning as in section 3722.01
of the Revised Code and includes a hospital owned or operated by
the United States department of veterans affairs.

(3) "Identified" means that a hospital or inpatient
facility pharmacist has determined that the drug in question is



6zutxyinferfbqgxc54h9

the drug prescribed by the patient's prescriber and that the 17
patient's prescribed drug is in the original manufacturer's 18
packaging or is labeled from an outpatient retail pharmacy, has 19
been approved by the prescriber for use, and is not outside of 20
its beyond use date. 21

(4) "Informed consent" means the communication between a 22
patient, patient's parent/guardian, or person holding a health 23
care power of attorney and a physician that results in the 24
patient, patient's parent/guardian, or person holding a health 25
care power of attorney authorizing, or agreeing to accept, a 26
specific drug, treatment, or intervention. The physician, as 27
part of such communication, shall provide all of the following 28
information: the patient's diagnosis, if known; the nature and 29
purpose of the recommended drug, treatment, or intervention; the 30
burdens, risks, and expected benefits of all drug, treatment, or 31
intervention options, including the option of forgoing 32
treatment; and any conflicts of interest the physician may have 33
regarding the recommended drug, treatment, or intervention. 34

(5) "Inpatient facility" means either or both of the 35
following: 36

(a) A skilled nursing facility as defined in section 37
5165.01 of the Revised Code; 38

(b) A freestanding inpatient rehabilitation facility 39
licensed under section 3702.30 of the Revised Code. 40

(6) "Off-label drug" means a drug that meets all of the 41
following: 42

(a) The drug is approved by the United States food and 43
drug administration to treat or prevent a disease, illness, or 44
infection, but prescribed for or used by a patient to treat or 45

prevent another disease, illness, or infection. 46

(b) The drug is legal for use in this state. 47

(c) The drug is not a controlled substance as defined in 48
section 3719.01 of the Revised Code. 49

(7) "Pharmacist" means an individual who holds a license 50
issued under section 4729.08 of the Revised Code authorizing the 51
individual to practice pharmacy. 52

(8) "Political subdivision" means a county, township, 53
municipal corporation, school district, or other body corporate 54
and politic responsible for governmental activities in a 55
geographic area smaller than that of the state. "Political 56
subdivision" also includes a board of health of a city or 57
general health district. 58

(9) "Prescriber" has the same meaning as in section 59
4729.01 of the Revised Code. 60

(10) "Public official" means any officer, employee, or 61
duly authorized agent or representative of a state agency or 62
political subdivision. 63

(11) "State agency" means any organized agency, board, 64
body, commission, department, institution, office, or other 65
entity established by the laws of the state for the exercise of 66
any function of state government. "State agency" does not 67
include a court. 68

(B) A prescriber may issue for a patient a prescription 69
for any drug, including an off-label drug, if the prescriber has 70
obtained the informed consent of any of the following: the 71
patient, patient's parent/guardian, or person holding the 72
patient's health care power of attorney. All of the following 73

apply to the prescribing of an off-label drug under this 74
division: 75

(1) The prescriber is not required to obtain or show a 76
test result for a particular disease, illness, or infection 77
before issuing the prescription for the patient's use of the 78
drug at home or for outpatient treatment or in a hospital or 79
inpatient facility. 80

(2) The patient is not required to have had a positive 81
screen or test result for a particular disease, illness, or 82
infection before the prescriber issues the prescription. 83

(3) The patient is not required to have been exposed to a 84
disease, illness, or infection before the prescriber issues the 85
prescription for the patient's prophylactic use of the drug. 86

(4) In the case of a drug subject to a United States food 87
and drug administration risk evaluation and mitigation strategy, 88
the usage of the drug for an off-label purpose must be 89
consistent with any requirements or recommendations the strategy 90
establishes. 91

(C)(1) A pharmacist shall dispense, and a hospital or 92
inpatient facility shall allow the dispensing of, an off-label 93
drug to a patient if a prescriber has issued for the patient a 94
prescription for the drug as described in division (B) of this 95
section, except if either of the following is the case: 96

(a) As provided in section 4743.10 of the Revised Code, 97
the pharmacist, hospital, or inpatient facility has a moral, 98
ethical, or religious belief or conviction that conflicts with 99
the drug's dispensing. 100

(b) The pharmacist has documented that the patient has a 101
history of a life-threatening allergic reaction to the 102

prescribed off-label drug or there is a life-threatening 103
contraindication. 104

(2) When a pharmacist must dispense, or a hospital or 105
inpatient facility must allow the dispensing of, an off-label 106
drug for a patient pursuant to this section, but the pharmacist, 107
hospital, or inpatient facility has an objective, good faith, 108
and scientific objection to the administration or dosage of the 109
drug for that patient, the pharmacist, hospital, or inpatient 110
facility shall be immune from administrative or civil liability 111
for any harm that may arise from the dispensing or use of the 112
off-label drug starting from the date of dispensing, so long as, 113
at the time of dispensing, the pharmacist, hospital, or 114
inpatient facility documents in the patient's medical record the 115
objective, good faith, and scientific objection, by stating with 116
particularity the basis of that objection, which must be based 117
on an individualized assessment of the patient and the off-label 118
drug. 119

(3) (a) In the case of a pharmacist who practices within a 120
hospital's or inpatient facility's pharmacy and where an in- 121
house treating prescriber issues for a hospital or facility 122
patient a prescription for an off-label drug that is neither in 123
stock nor listed on the hospital's or facility's formulary, the 124
pharmacist must document in the patient's medical record that a 125
good faith effort was made to find out if the drug is available 126
from another hospital or inpatient facility or another United 127
States distributor. If available, the drug must be offered to 128
the patient at an upfront out-of-pocket cost to the patient. The 129
hospital or inpatient facility may require payment prior to 130
ordering the drug. 131

(b) If the hospital or inpatient facility pharmacist is 132

unable to obtain the off-label drug from another hospital, 133
inpatient facility, or distributor or if the hospital, hospital 134
pharmacist, inpatient facility, or pharmacist declines to fill 135
the prescription for the reasons provided in section 4743.10 of 136
the Revised Code, and the patient has access to the drug through 137
a pharmacy outside the hospital or inpatient facility or has the 138
drug available at home, then both of the following apply: 139

(i) The hospital or inpatient facility must permit that 140
drug to be brought into the hospital or inpatient facility to be 141
identified for the patient's use. If identified, the drug will 142
be administered to the patient within the hospital or inpatient 143
facility. 144

(ii) When the hospital or inpatient facility or the 145
patient's in-house treating prescriber or other in-house 146
treating clinician is unwilling to administer the identified 147
drug to the patient for reasons provided in section 4743.10 of 148
the Revised Code, then another prescriber or prescriber's 149
delegate may administer the drug. 150

(4) When a patient's condition is so serious that the 151
patient cannot be safely transported out of a hospital or 152
inpatient facility and the patient, patient's parent/guardian, 153
or person holding the patient's health care power of attorney 154
wishes to try an off-label drug to treat the patient's 155
condition, but there is no in-house prescriber willing to 156
prescribe the drug, then the patient's outpatient physician 157
prescriber, after a prompt consultation with the patient's 158
hospital or inpatient facility care team and a review of all of 159
the patient's drugs, shall be allowed to immediately begin 160
applying for temporary privileges with oversight, based on 161
criteria within the hospital or inpatient facility medical staff 162

bylaws used to determine the issuance of temporary privileges. 163
The temporary privileges approval process is not to exceed five 164
days. 165

If the outpatient physician prescriber does not meet the 166
hospital's or facility's medical staff bylaw requirements and 167
the outpatient physician prescriber feels that temporary 168
privileges were wrongfully denied to the physician, then the 169
physician may file a complaint with the department of health. 170
The complaint shall include the name of the hospital or 171
facility, the hospital's or facility's stated reason for the 172
denial, and the name of the drug that the outpatient physician 173
prescriber was seeking temporary privileges in order to 174
prescribe. The department shall keep a record of the complaint, 175
including the aforementioned information. The complaint's 176
information shall be kept on file with the department for seven 177
years and shall be made available to any citizen of this state 178
within ten days of the citizen's written request. 179

If the outpatient physician prescriber meets the 180
hospital's or facility's medical staff bylaw requirements for 181
temporary privileges, then he/she shall immediately be allowed 182
to participate in the patient's care in the narrowed scope of 183
practice regarding the administering and monitoring of the 184
prescribed off-label drug within the hospital or inpatient 185
facility until the patient is in a condition where the patient 186
can be safely transported to a hospital or inpatient facility 187
where the outpatient physician prescriber has privileges. In 188
such a case, all of the following apply: 189

(a) The patient may be required to pay out-of-pocket for 190
the prescribed off-label drug before it is ordered. 191

(b) If the hospital or inpatient facility cannot obtain 192

the off-label drug being prescribed by the outpatient physician 193
prescriber, then the requirements of divisions (C) (3) (b) (i) and 194
(ii) apply. 195

(c) The in-house pharmacist, hospital, or inpatient 196
facility and the in-house physician responsible for the 197
patient's care shall be immune from administrative and civil 198
liability for any harm that may arise from the patient's use of 199
the off-label drug prescribed by the outpatient physician 200
prescriber starting from the date of dispensing. 201

(5) All of the following apply to the dispensing of an 202
off-label drug under division (C) (1) or (2) of this section: 203

(a) The pharmacist is not required to obtain or show a 204
test result before dispensing the drug for the patient's use at 205
home or for other outpatient treatment. 206

(b) The patient is not required to have had a positive 207
screen or test result for a particular disease, illness, or 208
infection before the pharmacist dispenses the drug. 209

(c) The patient is not required to have been exposed to a 210
disease, illness, or infection before the pharmacist dispenses 211
the drug for prophylactic use. 212

(6) Nothing in this section prevents a pharmacist from 213
discussing a prescription with the prescriber who issued the 214
prescription. The ultimate decision to accept a drug prescribed 215
by the prescriber shall be made by one of the following who has 216
given informed consent: the patient, patient's parent/guardian, 217
or person holding the patient's health care power of attorney. 218

(D) A health-related licensing board, department of 219
health, state board of pharmacy, or other state board or agency 220
responsible for the licensure or regulation of health care 221

professionals shall not consider any action taken by a 222
prescriber or pharmacist or hospital or inpatient facility under 223
this section to be unlawful, unethical, unauthorized, or 224
unprofessional conduct and shall not pursue an administrative or 225
disciplinary action against the prescriber, pharmacist, 226
hospital, or facility, except in cases of recklessness or gross 227
negligence. 228

A health-related licensing board, department of health, 229
state board of pharmacy, or other state board or agency 230
responsible for the licensure or regulation of health care 231
professionals shall not pursue an administrative or disciplinary 232
action against a prescriber, pharmacist, or other licensed 233
health care professional or hospital or inpatient facility for 234
publicly or privately expressing a medical opinion that does not 235
align with the opinions of the board or agency, a board of 236
health of a city or general health district, or the department 237
of health. 238

(E) The world health organization shall have no 239
jurisdiction in this state. Therefore, no political subdivision, 240
public official, or state agency shall enforce or use any state 241
funding to implement any guideline, mandate, recommendation, or 242
rule issued by the world health organization that prohibits 243
issuing a prescription for or dispensing an off-label drug. 244

(F) At no time shall a patient in a hospital or inpatient 245
facility be denied sufficient means of fluids or nutrition, 246
unless that wish is clearly stated in the patient's end of life 247
health directive, as that directive is defined by the patient, 248
patient's parent/guardian, or person holding the patient's 249
health care power of attorney, or the denial is necessary for a 250
medical procedure, including a diagnostic or surgical procedure, 251

and then only for the shortest amount of time medically possible 252
and with the informed consent of the patient or person holding 253
the patient's health care power of attorney. 254

Section 2. This act shall be known as the Dave and Angie 255
Patient and Health Provider Protection Act. 256